1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,154 | 0,175 | 14:20 | |
| 0,154 | 0,173 | 14:20 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.11.25 | BRII-B (02137): VOLUNTARY ANNOUNCEMENT PRESENTS LATE-BREAKING DATA FROM ONGOING PHASE 2 ENSURE STUDY AT AASLD 2025 | 1 | HKEx | ||
| 07.11.25 | BRII-B (02137): VOLUNTARY ANNOUNCEMENT PUBLICATION OF PHASE 2 ENSURE STUDY RESULTS IN NATURE MEDICINE | - | HKEx | ||
| 31.10.25 | BRII-B (02137): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| 28.10.25 | BRII-B (02137): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | 1 | HKEx | ||
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.10.25 | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 18.09.25 | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 18.09.25 | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
| 18.09.25 | BRII-B (02137): 2025 INTERIM REPORT | - | HKEx | ||
| 17.09.25 | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 21.08.25 | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results | 148 | PR Newswire | Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy
Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic... ► Artikel lesen | |
| 30.03.25 | Brii Biosciences Limited: Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification | 159 | PR Newswire | Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and... ► Artikel lesen | |
| 21.03.25 | Brii Biosciences Limited: Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results | 683 | PR Newswire | Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure
Data... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 161,85 | -0,31 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| ILLUMINA | 113,76 | -0,05 % | Evercore ISI reiterates Illumina stock rating on competitive positioning | ||
| NANOREPRO | 1,540 | -1,60 % | EQS-Adhoc: NanoRepro AG: NanoRepro beschließt Barkapitalerhöhung mit Bezugsrechtsausschluss aus genehmigtem Kapital im Umfang von bis zu 10% des Grundkapitals | EQS-Ad-hoc: NanoRepro AG / Schlagwort(e): Kapitalmaßnahmen / Kapitalerhöhung
NanoRepro AG beschließt Barkapitalerhöhung mit Bezugsrechtsausschluss aus genehmigtem Kapital... ► Artikel lesen | |
| BRAIN BIOTECH | 2,430 | -2,80 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech verkündet 3M-Zahlen 2025/26 und Durchbruch bei BRAINBioIncubator-Beteiligung SolasCure: Aurase Wound Gel zeigt starke klinische Wirkung bei Wundreinigung und Heilung chronischer ... | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Quartals-/Zwischenmitteilung/Studienergebnisse
BRAIN Biotech verkündet 3M-Zahlen 2025/26 und Durchbruch bei BRAINBioIncubator-Beteiligung... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,385 | -1,53 % | BioNxt Solutions Inc.: BioNxt Announces Closing of Shares for Debt Settlement | VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated... ► Artikel lesen | |
| INFLARX | 0,785 | +0,77 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp: Sirona Biochem downgraded to NEX | ||
| DEFENCE THERAPEUTICS | 0,371 | -1,85 % | Defence Therapeutics Inc.: Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March | Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| BURCON NUTRASCIENCE | 1,430 | +2,14 % | Burcon NutraScience Corporation: Burcon Closes Second Tranche of Non-Brokered Private Placement of Convertible Debentures of up to $6.9 Million | Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| TME PHARMA | 0,067 | +16,52 % | TME Pharma NV: TME Pharma provides update on its activities | TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| CYTODYN | 0,210 | 0,00 % | CytoDyn Inc.: December 2025 Letter to Shareholders | VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your... ► Artikel lesen | |
| IMMUNIC | 0,851 | -1,05 % | EQS-News: Immunic AG: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Annual Results
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
26.02.2026 / 12:30 CET/CEST
The... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,188 | -3,06 % | Iovance Biotherapeutics, Inc.: Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas | 50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,135 | 0,00 % | Quantum XChange treibt mit der neuesten Version von Phio TX einen EUCC-Meilenstein und die Skalierbarkeit für Unternehmen voran | Neuer EUCC-Compliance-Modus und bessere Hive-Architektur stärken die Sicherheit für regulierte europäische und globale Netzwerke Quantum XChange hat heute die neueste Version seiner Kryptografie-Managementplattform... ► Artikel lesen |
Das Unternehmen BRII BIOSCIENCES LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,161 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRII BIOSCIENCES LTD finden Sie auf Wallstreet Online.